COMMENTARY: Review: Clonidine is more effective than placebo for long-term smoking cessation but has side effects

Bentz, Charles J.
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p12
Academic Journal
The article reports that clonidine is more effective than placebo for long-term smoking cessation but has side effects. The systematic review supports the conclusions of the U.S. Public Health Service clinical guideline on treating tobacco use and dependence. Clinicians should now have confidence that clonidine, along with nicotine replacement therapy and antidepressant therapy is an effective option for helping tobacco users quit. Clonidine is considered a second-line medication for several reasons.


Related Articles

  • FDA's postmarketing review of varenicline and bupropion.  // Reactions Weekly;1/24/2009, Issue 1236, p3 

    The article reports on the postmarketing review of Adverse Event Reporting System reports by the U.S. Food and Drug Administration (FDA) which identified cases of suicidal ideation and behaviours after taking varenicline and bupropion for smoking cessation. 41 percent of varenicline recipients...

  • Preexposure to nicotine alters the subsequent locomotor stimulant effects of bupropion in rats. Wilkinson, Jamie; Palmatier, Matthew; Bevins, Rick // Nicotine & Tobacco Research;Feb2006, Vol. 8 Issue 1, p141 

    Little is known about the interaction between nicotine and bupropion (Zyban), but many studies suggest they have neurological and behavioral similarities. One feature of drugs with common profiles is the ability to cross-sensitize possibly through neurological changes in the reward pathway....

  • Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;1/8/2002, Vol. 166 Issue 1, p68 

    Focuses on suspected adverse drug reactions for bupropion, including reports of a number of deaths, seizures or convulsions, and serum-sickness-like reactions. How the drug appears to block noradrenergic reuptake and dopaminergic reuptake in the brain, and is used as an antidepressant and...

  • Nicotine conjugate vaccines: A novel approach in smoking cessation. Kitchens, Caroline M.; Foster, Stephan L. // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2012, Vol. 52 Issue 1, p116 

    The article discusses pharmacologic therapeutic options for smoking cessation in the U.S. These options are direct nicotine replacement therapy (NRT), anti-depressant medications and a nicotine receptor partial agonist. Dosage forms of NRT include chewing gums, lozenges, patches, nasal sprays...

  • Antidepressants and Smoking Cessation. Kripke, Clarissa // American Family Physician;1/1/2005, Vol. 71 Issue 1, p67 

    Focuses on antidepressants that help patients stop smoking. Factors that increase the rates of abstinence from smoking; Practices approved by the U.S. Food and Drug Administration for use in smoking cessation; Antidepressants that improve rates of smoking cessation.

  • Bupropion (Zyban, sustained-release tablets): update. Dunlop, Heather // CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p106 

    Reports adverse drug reactions (ADRs) to bupropion (Zyban, sustained-release tablets), which is used for smoking cessation. Number and type of reactions to Zyban as reported to the Canadian Adverse Drug Reaction Monitoring Program; ADRs, including central and peripheral nervous system,...

  • creating a healthier life. Rouse, Debra // Better Nutrition;Apr2007, Vol. 69 Issue 4, p46 

    The article discusses how to quit smoking through natural therapy. According to the author, addiction to nicotine is very difficult to overcome, because smoking is a physical and behavioral compulsion. Drugs have a low success rate, and also have side effects. In natural methods, the behaviors...

  • Chantix and neuropsychiatric side effects. Elliott, William T. // Primary Care Reports;Dec2011 Pharmacology Watch, p2 

    The article presents the findings of two epidemiologic studies sponsored by the U.S. Food and Drug Administration (FDA) in 2011 which showed no difference in the risk of neuropsychiatric hospitalization between smoking cessation drug varenicline (Chantix) and nicotine replacement therapy.

  • Antismoking drug comes under scrutiny after deaths. Dobson, Roger // BMJ: British Medical Journal (International Edition);02/24/2001, Vol. 322 Issue 7284, p452 

    Addresses complaints filed against the manufacturers of the antismoking drug amfebutamone (Zyban), following the deaths of 18 people who are suspected to have had adverse reactions to the drug. How the Medicines Control Agency said that the contribution of the drug to the deaths is unknown;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics